Abstract
Monoclonal κ and λ immunoglobulin free light chains (FLC) in blood and urine are important biomarkers to determine if acute kidney injury (AKI) may be attributable to a plasma cell dyscrasia. Laboratory FLC tests offer the only means of detecting FLC and commonly have a slow turnaround time that delays early diagnosis of myeloma kidney and thus increases risk of kidney damage. We have developed a point-of-care (POC) lateral flow test that can rapidly measure FLC levels in blood or urine in 10 minutes. The POC test simultaneously quantitates κ and λ FLC levels using highly specific anti-κ and anti-λ FLC monoclonal antibodies (abstract also submitted). POC capture antibodies displayed no cross-reactivity to bound LC on whole immunoglobulin, the alternate LC type, or other human proteins, and had excellent sensitivity
| Original language | English |
|---|---|
| Pages (from-to) | 253-254 |
| Number of pages | 2 |
| Journal | Clinical Lymphoma, Myeloma and Leukemia |
| Volume | 13 |
| Publication status | Published - 1 Apr 2013 |
Keywords
- immunoglobulin
- monoclonal antibody
- antigen
- protein
- antibody
- myeloma
- serum
- kidney
- light chain
- identity
- workshop
- rapid test
- human
- urine
- patient
- blood
- kidney injury
- risk
- early diagnosis
- clinical practice
- turnaround time
- laboratory
- plasma cell dyscrasia
- cross reaction
- competitive inhibition
- donor
- acute kidney failure